Italy’s pharmaceutical reform bill has moved into a more detailed parliamentary debate on the mechanisms used to manage medicine availability, expenditure and implementation across regions.
The bill under examination in the Senate concerns the reform and reorganisation of pharmaceutical legislation in four areas: access to medicines, monitoring and control of pharmaceutical expenditure, health services delivered through community pharmacies, and strengthening of the pharmaceutical assistance network. That initial scope places the measure within Italy’s medicines-access and spending-control framework, but leaves much of the practical model to be developed through the legislative process.
Amendments tabled by the governing majority would add more specific instruments to that framework. They include immediate access to orphan medicines after marketing authorisation and before completion of standard pricing and reimbursement procedures, with subsequent alignment once the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) completes its assessment. They also propose faster routes for innovative medicines and wider use of horizon scanning to anticipate clinical, organisational and budget effects before products enter routine decision-making.
The amendments also address regional variation in access. The proposals include measures intended to ensure more uniform availability of medicines across the National Health Service, reducing differences in uptake and implementation between regions after national decisions have been made.
On expenditure control, the amendments would revise pharmaceutical spending caps and reduce the burden of payback, with the possibility of replacing the current mechanism. They would also link medicines management more closely to outcomes, appropriateness and real-world data. Wider use of health-data systems and artificial intelligence would support expenditure monitoring and assessment of therapeutic results.
The amendments also cover off-patent competition and differentiated assessment routes. Equivalents and biosimilars would be placed automatically in the same reimbursement class as the originator. Value-added medicines would receive a dedicated pathway, while advanced therapies and other high-impact innovations would be supported through specific financing tools. Research investment would also be taken into account in the management of pharmaceutical expenditure and access policy.
The proposals remain amendments to a bill under parliamentary examination. If retained, they would make the reform more concrete in areas that have long shaped Italian market access: early availability, payback exposure, expenditure caps, regional consistency, data-linked medicines management and the handling of high-cost innovation.
Source: Senate of the Republic and Quotidiano Sanità
Link: Resoconto sommario n. 406 della 10ª Commissione permanente (Summary report no. 406 of the 10th Standing Committee).
Link: Riforma farmaceutica. Dall’early access al payback, fino a farmaci critici, IA e farmacie dei servizi: le mosse della maggioranza sulla delega (Pharmaceutical reform. From early access to payback, through critical medicines, AI and service pharmacies: the majority’s moves on the delegation bill).
Date: 19 May 2026 and 25 May 2026
